NFKB1 and hematologic disorder: The use of our ex vivo BMEC expansion platform to identify NF-κB signalling as a key regulatory pathway in the BM vascular niche has unlocked the potential for a cellular therapy approach to treat haematopoietic disease requiring cytotoxic regimens.